Hypoxia inducible factor (HIF1α and HIF2α) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy

References

• Aebersold D M, Burri P, Beer K T, Laissue J, Djonov V, Greiner R H, Semenza G L. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research 2001; 61: 2911–2916
   PubMed Web of Science ®Google Scholar
• Brown L M, Cowen R L, Debray C, Eustace A, Erler J T, Sheppard F C, Parker C A, Stratford I J, Williams K J. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Molecular Pharmacology 2006; 69: 411–418
   PubMed Web of Science ®Google Scholar
• Chen L, Uchida K, Endler A, Shibasaki F. Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2 alpha for degradation by hypoxia- and pVHL-independent regulation. Journal of Biological Chemistry 2007; 282: 12707–12716
   PubMed Web of Science ®Google Scholar
• Dewhirst M W. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Research 2007; 67: 854–855
   PubMed Web of Science ®Google Scholar
• Dische S. Radiotherapy and anaemia – the clinical experience. Radiotherapy and Oncology 1991a; 20(Suppl.)35–40
   PubMedGoogle Scholar
• Dische S. What have we learnt from hyperbaric oxygen?. Radiotherapy and Oncology 1991b; 20(Suppl. 1)71–74
   PubMedGoogle Scholar
• Gatenby R A, Gillies R J. Why do cancers have high aerobic glycolysis?. Nature Review Cancer 2004; 4: 891–899
   PubMed Web of Science ®Google Scholar
• Kaluz S, Kaluzova M, Stanbridge E J. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Research 2003; 63: 917–922
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy?. International Journal of Radiation Oncology Biology and Physics 2000; 48: 545–553
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff C C, Gatter K C, Harris A L. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clinical Cancer Research 2001; 7: 3399–3403
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter K C, Harris A L. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology Biology and Physics 2002; 53: 1192–1202
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Bentzen S M, Giatromanolaki A, Wilson G D, Daley F M, Saunders M I, Dische S, Sivridis E, Harris A L. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomised trial. Journal of Clinical Oncology 2006; 24: 727–735
   PubMed Web of Science ®Google Scholar
• Kumar P. Tumour hypoxia and anemia: impact on the efficacy of radiation therapy. Seminars in Hematology 2000; 37(Suppl 6)4–8
   PubMedGoogle Scholar
• Lee D J. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. International Journal of Radiation Oncology Biology and Physics 1995; 32: 567–576
   PubMed Web of Science ®Google Scholar
• Malaise P E, Fertil B, Chavaudra N, Guichard M. Distribution of radiation sensitivities for human tumor cells of specific histological types: Comparison of in vitro to in vivo data. International Journal of Radiation Oncology Biology and Physics 1986; 12: 617–624
   PubMed Web of Science ®Google Scholar
• Moeller B J, Dewhirst M W. HIF-1 and tumour radiosensitivity. British Journal of Cancer 2006; 95: 1–5
   PubMed Web of Science ®Google Scholar
• Moeller B J, Dreher M R, Rabbani Z N, Schroeder T, Cao Y, Li C Y, Dewhirst M W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8: 99–110
   PubMed Web of Science ®Google Scholar
• Ratcliffe P J. HIF-1 and HIF-2: working alone or together in hypoxia?. Journal of Clinical Investigations 2007; 117: 862–865
   PubMed Web of Science ®Google Scholar
• Semenza G L, Shimoda L A, Prabhakar N R. Regulation of gene expression by HIF-1. Novartis Foundation Symposium 2006; 272: 2–8
   PubMedGoogle Scholar
• Sowter H M, Raval R, Moore J, Ratcliffe P J, Harris A L. Predominant role of hypoxia-inducible transcription factor Hif-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Research 2003; 63: 6130–6134
   PubMed Web of Science ®Google Scholar
• Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL−/− renal cancer. Cancer Research 2005; 65: 5221–5230
   PubMed Web of Science ®Google Scholar
• Talks K L, Turley H, Gatter K C, Maxwell P H, Pugh C W, Ratcliffe P J, Harris A L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. American Journal of Pathology 2000; 157: 411–421
   PubMed Web of Science ®Google Scholar
• Tubiana M, Dutreix J, Wambersie A, Bewley D K. Hypoxic cells and their importance in radiotherapy. Introduction to radiobiology, M Tubiana, J Dutreix, A Wambersie, D K Bewley. Taylor & Francis, London 1990; 210–224
   Google Scholar
• Wang V, Davis D A, Haque M, Huang L E, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Research 2005; 65: 3299–3306
   PubMed Web of Science ®Google Scholar
• Warburg O. The metabolism of tumors. R. R. Smith, Inc., New York 1931
   Google Scholar
• Williams K J, Telfer B A, Xenaki D, Sheridan M R, Desbaillets I, Peters H J, Honess D, Harris A L, Dachs G U, van der Kogel A, Stratford I J. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy and Oncology 2005; 75: 89–98
   PubMed Web of Science ®Google Scholar
• Zhong H, De Marzo A M, Laughner E, Lim M, Hilton D A, Zagzag D, Buechler P, Isaacs W B, Semenza G L, Simons J W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Research 1999; 59: 5830–5835
   PubMed Web of Science ®Google Scholar